ASAN FOUNDATION

Nelonemdaz Shows Promise in Treating Out-of-Hospital Cardiac Arrest Patients

4 months ago

A recent clinical trial has highlighted the potential of Nelonemdaz in treating patients who have suffered out-of-hospital cardiac arrest. The study, supported by the Ministry of Health and Welfare of the Republic of Korea and GNT Pharma, involved multiple institutions and adhered to strict ethical guidelines, offering new hope for improving survival and recovery outcomes.

Comparative Study on Cefoxitin Administration Methods for Preventing Surgical Site Infections

4 months ago

A randomized controlled trial compares the effectiveness of the target-controlled infusion (TCI) method versus the standard method for administering cefoxitin to prevent surgical site infections (SSI) in colorectal surgery patients.

Real-World AVION Study Affirms Avelumab Plus Axitinib Efficacy in Advanced Renal Cell Carcinoma

5 months ago

• The AVION study demonstrated that first-line avelumab plus axitinib is effective and safe for advanced renal cell carcinoma (RCC) in real-world settings. • The 12-month overall survival rate was 82.7% among patients receiving the combination therapy, aligning with results from prior clinical trials. • Common treatment-related adverse events included diarrhea, fatigue, and hypertension, with manageable safety profiles and stable health-related quality of life. • These findings support the use of avelumab plus axitinib as a frontline treatment option for advanced RCC, reinforcing its clinical benefit.

Early Hepatitis B Treatment with Vemlidy Shows Promise in Preventing Liver Cancer

6 months ago

• Interim analysis of the ATTENTION trial suggests early treatment with Vemlidy (tenofovir alafenamide) significantly reduces liver-related events in hepatitis B patients. • The study found a 79% lower risk of liver disease-related events in the Vemlidy arm compared to the observation arm (HR=0.21, 99.997% CI 0.01-5.45). • Experts advocate for revising treatment guidelines to include viral load as a key metric, potentially preventing thousands of liver cancer cases annually. • The ATTENTION study highlights the potential for early intervention to reduce healthcare costs and improve patient outcomes in chronic hepatitis B.

Pharos iBio's PHI-101 Demonstrates Promising Complete Response in AML Phase 1 Trial

7 months ago

• Pharos iBio's PHI-101, a first-in-class treatment for acute myeloid leukemia (AML), achieved a 50% overall complete response rate in a Phase 1 study. • The study included patients who relapsed or failed after prior FLT3 inhibitor therapy, with 75% falling into this category, highlighting PHI-101's potential. • Pharos iBio plans to complete Phase 1 and file an IND application for a global Phase 2 trial, aiming for early commercialization via conditional marketing authorization. • Data from the expanded Phase 1b study of PHI-101-AML will be presented at the American Society of Hematology (ASH) Annual Meeting in December.

TiumBio Doses First Patient in Phase 2 Trial of Oral Immuno-Oncology Drug TU2218

8 months ago

• TiumBio has dosed the first patient in a Phase 2 clinical trial of TU2218, an oral dual inhibitor targeting TGFR1 and VEGFR2. • The Phase 2a trial will evaluate TU2218 in combination with Keytruda for head and neck squamous cell carcinoma, biliary tract cancer and colorectal cancer. • Phase 1b trial data showed a 80% disease control rate when TU2218 was combined with Keytruda in advanced solid tumor patients.

Amlodipine and Candesartan Combination Therapy Shows Superior Efficacy in Treating Hypertension

8 months ago

• A Phase III clinical trial demonstrates that a combination of amlodipine and candesartan is more effective than amlodipine alone in reducing diastolic blood pressure in hypertensive patients. • The study, involving Korean patients with essential hypertension, showed significant reductions in both diastolic and systolic blood pressure with the combination therapy. • The fixed-dose combination of amlodipine and candesartan was well-tolerated, with adverse events comparable to those observed with amlodipine monotherapy. • These findings support the use of amlodipine and candesartan combination therapy as an effective treatment option for patients whose hypertension is not adequately controlled by amlodipine alone.

FDA Authorizes Phase 2a Trial of Progerinin for Hutchinson-Gilford Progeria Syndrome

8 months ago

• The FDA has authorized a Phase 2a clinical trial for Progerinin, a novel drug developed by PRG Science & Technology for Progeria treatment. • The trial will evaluate Progerinin in combination with Zokinvy, the current standard of care, in 10 patients with Progeria and Progeroid Laminopathies. • Progerinin has shown promise in preclinical studies, potentially increasing lifespan in a Progeria mouse model by 50%. • This trial represents a collaborative effort between PRG S&T, The Progeria Research Foundation, Boston Children’s Hospital, and Amarex CRO.

Sacituzumab Govitecan Demonstrates Efficacy in HR+/HER2- Metastatic Breast Cancer

8 months ago

• Sacituzumab govitecan (SG) significantly improved progression-free survival (PFS) compared to chemotherapy in patients with HR+/HER2- metastatic breast cancer. • The phase 3 EVER-132-002 trial included patients who had received two to four prior chemotherapy regimens, showing SG's benefit in heavily pre-treated populations. • SG demonstrated a manageable safety profile, supporting its potential as a valuable treatment option for this patient population in regions including mainland China, Republic of Korea and Taiwan. • The study's findings contribute to addressing the unmet need for effective therapies in HR+/HER2- metastatic breast cancer, particularly after multiple lines of treatment.

ROTEM-Guided TXA Administration vs. Preemptive TXA for Bleeding in Cardiovascular Surgery: A Randomized Trial

8 months ago

• A multi-center, double-blind, randomized trial is underway to compare ROTEM-guided tranexamic acid (TXA) administration with preemptive TXA in cardiovascular surgery patients. • The study aims to determine if ROTEM-guided TXA is non-inferior to preemptive TXA in reducing postoperative blood loss, with recruitment ongoing until December 2024. • The trial will also assess secondary outcomes such as blood transfusion rates, coagulation profiles, thromboembolic complications, and hospital costs. • Findings from this pragmatic trial will inform clinical practice by evaluating the effectiveness of ROTEM-guided TXA in real-world settings.

Fecal Microbiota Transplants Show Promise in Overcoming Immunotherapy Resistance in GI Cancers

8 months ago

• A South Korean study suggests fecal microbiota transplants (FMTs) may enhance immunotherapy efficacy in gastrointestinal (GI) cancer patients resistant to anti-PD-1 drugs. • The study found that 46.2% of patients with metastatic solid tumors refractory to nivolumab benefited from FMTs, showing tumor shrinkage in some cases. • Specific bacterial strains, like *Prevotella merdae*, improved FMT effectiveness, while others, such as *Lactobacillus salivarius*, had detrimental impacts. • Researchers emphasize the need for efficient FMT production methods and further clinical trials to integrate FMT into standard cancer treatment.

Flexible Antiplatelet Management Safe After Drug-Eluting Stent Implantation

9 months ago

• A recent trial suggests that discontinuing antiplatelet therapy around non-cardiac surgery is non-inferior to continuing aspirin monotherapy for patients with prior drug-eluting stent (DES) implantation. • The ASSURE DES trial found no significant difference in the composite outcome of death, myocardial infarction, stent thrombosis, or stroke between the two antiplatelet strategies. • Minor bleeding was slightly more frequent with aspirin monotherapy, indicating a potential benefit in temporarily withholding antiplatelet agents in select patients. • These findings support a flexible approach to antiplatelet management, but further research is needed for high-risk patients and surgeries.

GI Innovation and MSD Collaborate on GI-102 and Keytruda Combination Trial for Resistant Cancers

9 months ago

• GI Innovation partners with MSD to evaluate GI-102 combined with Keytruda (pembrolizumab) in a Phase II trial. • The trial targets metastatic liver cancer, melanoma, and renal cell carcinoma patients resistant to immunotherapy. • GI-102 previously demonstrated a 42.9% overall response rate in melanoma patients unresponsive to standard treatments. • The study will be conducted across 14 hospitals in South Korea and multiple sites in the US, including Mayo Clinic and Memorial Sloan Kettering.